Nocturia Market Report 2026

Nocturia Market Overview

• Nocturia market size has reached to $3.1 billion in 2025 • Expected to grow to $4.51 billion in 2030 at a compound annual growth rate (CAGR) of 7.7% • Growth Driver: Impact Of Cardiovascular Disease Prevalence On The Growth Of The Market • Market Trend: Impact Of Orally Disintegrating Tablets On Treatment Compliance And Outcomes • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Nocturia Market?

Nocturia is a medical condition characterized by the need to wake up at night one or more times to urinate. It is considered a lower urinary tract symptom (LUTS) and can result from various underlying causes, including excessive fluid intake before bedtime, overactive bladder, urinary tract infections, diabetes, or prostate enlargement in men. Nocturia can significantly impact sleep quality and overall health, leading to fatigue and decreased daytime productivity. The main drugs of nocturia are anticholinergic drugs, desmopressin, antibiotics, antispasmodics, and other medications. Anticholinergic drugs block acetylcholine to reduce involuntary bladder contractions, helping manage overactive bladder and nocturia. The main clinical indications for these drugs are mixed nocturia, low nocturnal bladder capacity, nocturnal polyuria, and global polyuria. Nocturia can be caused by urological infections, bladder tumors, diuretic medications, regular alcohol or coffee consumption, liver infections, diabetes, pregnancy, and other factors. These drugs are used by various end users, including hospitals, home care settings, and clinics.

What Is The Nocturia Market Growth Forecast?

The nocturia market size is expected to see strong growth in the next few years. It will grow to $4.51 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to growing demand for personalized treatment, expansion of home care therapies, increasing healthcare expenditure, rising focus on sleep quality management, improved access to urology specialists. Major trends in the forecast period include rising geriatric population and age-related urological disorders, increasing prevalence of diabetes and metabolic disorders, growing awareness and diagnosis of lower urinary tract symptoms, shift toward combination drug therapies, expansion of home-based nocturia management.

Global Nocturia Market Segmentation

1) By Drug: Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic, Other Drugs 2) By Indication: Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria, Global Polyuria 3) By Causes: Urological Infection, Tumor Of The Bladder, Diuretic Medications, Regular Alcohol Or Coffee, Liver Infection, Diabetes, Pregnancy, Other Causes 4) By End User: Hospitals, Home Care, Clinics Subsegments: 1) By Anticholinergic Drugs: Oxybutynin, Tolterodine, Solifenacin, Darifenacin, Fesoterodine 2) By Desmopressin: Intranasal Desmopressin, Oral Desmopressin 3) By Antibiotics: Nitrofurantoin, Trimethoprim, Fosfomycin 4) By Antispasmodic: Hyoscine Butylbromide, Flavoxate 5) By Other Drugs: Alpha-Blockers, Beta-3 Agonists

What Is The Driver Of The Nocturia Market?

The growing prevalence of cardiovascular diseases is expected to propel the growth of the nocturia market going forward. Cardiovascular diseases (CVDs) are a group of disorders affecting the heart and blood vessels, including conditions such as heart disease, stroke, and hypertension. The prevalence of cardiovascular diseases can be attributed to factors such as aging populations, sedentary lifestyles, unhealthy diets, smoking, excessive alcohol consumption, obesity, high blood pressure, high cholesterol, diabetes, and genetic predisposition. Patients with cardiovascular diseases often experience nocturia as a symptom, leading to higher demand for diagnosis and treatment solutions. As cardiovascular conditions continue to rise globally due to aging populations and unhealthy lifestyles, the need for effective nocturia management will grow. For instance, in September 2025, according to the British Heart Foundation, a UK-based charity, across the UK, more than 7.6 million people over 4 million men and more than 3.6 million women are living with cardiovascular disease, and projections indicate that, driven by an aging population and improved survival rates, the number of affected individuals may rise by around 1 million by 2030 and by approximately 2 million by 2040. Therefore, the growing prevalence of cardiovascular diseases is driving the growth of the nocturia industry.

Key Players In The Global Nocturia Market

Major companies operating in the nocturia market are Pfizer Inc, Merck & Co. Inc, AbbVie Inc, Sanofi S.A, GlaxoSmithKline plc, Viatris Inc, Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd, Astellas Pharma Inc, Eisai Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd, Ferring Pharmaceuticals A/S, Avadel Pharmaceuticals plc, UroGen Pharma Ltd, Sanwa Kagaku Co. Ltd., Urovant Sciences Inc, Serenity Pharmaceuticals LLC, Vantia Therapeutics Inc, AA Pharma Inc, Wellesley Pharmaceuticals Inc

Global Nocturia Market Trends and Insights

Major companies operating in the nocturia market are focusing on developing innovative products, such as orally disintegrating tablets, to enhance patient convenience and compliance. Orally disintegrating tablets (ODTs) are solid dosage forms that dissolve quickly in the mouth without needing water, making them ideal for patients with difficulty swallowing. For instance, in July 2024, Adalvo Limited, a Malta-based pharmaceutical company, launched Desmopressin ODT in Europe to treat conditions that cause the body to lose too much fluid, such as central cranial diabetes insipidus. This synthetic form of vasopressin tablet treats diabetes insipidus, excessive thirst and urination, and bedwetting by mimicking the natural hormone and limiting the amount of water eliminated in urine. It is also used to manage bleeding in mild to moderate hemophilia A and von Willebrand disease by promoting the release of blood clotting factors.

What Are Latest Mergers And Acquisitions In The Nocturia Market?

In March 2023, KYORIN Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, entered into a licensing partnership with Sumitomo Pharma to commercialize the overactive bladder therapy vibegron in Taiwan, Hong Kong, Singapore, Indonesia, and Vietnam for an undisclosed amount. With this agreement, KYORIN aims to expand the regional footprint of its β3-adrenergic receptor agonist by leveraging Sumitomo Pharma’s development, manufacturing, and commercialization capabilities across high-growth Asian markets. Sumitomo Pharma is a Japan-based provider of pharmaceutical research, development, and commercialization solutions with a strategic focus on therapies for unmet medical needs.

Regional Outlook

North America was the largest region in the nocturia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Nocturia Market?

The nocturia market consists of revenues earned by entities by providing services such as diagnostic services, pharmacological treatment services, behavioral therapy and lifestyle modification services and telemedicine and remote consultation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The nocturia market also includes sales of bladder control devices, alpha-blockers, diuretics, and tricyclic antidepressants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Nocturia Market Report 2026?

The nocturia market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the nocturia industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.